Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand-Reference-Cited by-同舟云学术

Lipoprotein apheresis and PCSK9 inhibitors for severe familial hypercholesterolaemia: Experience from Australia and New Zealand

Published:2020-09-10 Issue:1 Volume:36 Page:48-58
ISSN:0733-2459
Container-title:Journal of Clinical Apheresis
language:en
Short-container-title:J Clin Apher

Author:

Page Michael M¹²^ORCID,Ekinci Elif I³⁴,Burnett John R¹⁵⁶,Hooper Amanda J¹⁵,Reid Nicola⁷,Bishop Warrick⁸,Florkowski Chris M⁷⁹,Scott Russell⁷,O'Brien Richard C³⁴,Watts Gerald F¹⁶

Affiliation:

1. School of Medicine University of Western Australia Crawley Western Australia Australia

2. Western Diagnostic Pathology Myaree Western Australia Australia

3. Department of Endocrinology Austin Health Heidelberg Victoria Australia

4. Department of Medicine, Austin Health University of Melbourne Heidelberg Victoria Australia

5. Department of Clinical Biochemistry, PathWest Laboratory Medicine Royal Perth Hospital and Fiona Stanley Hospital Perth Western Australia Australia

6. Lipid Disorders Clinic, Cardiovascular Medicine Royal Perth Hospital Perth Western Australia Australia

7. Cardiovascular Prevention and Lipid Disorders Clinic Christchurch Hospital Christchurch New Zealand

8. Calvary Cardiac Centre Calvary Hospital Lenah Valley Tasmania Australia

9. Canterbury Health Laboratories Christchurch New Zealand

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jca.21839

Reference38 articles.

1. PCSK 9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease